Amended Quarterly Activities/Appendix 4C Cash Flow

• Record full-year revenue of A$29.2 million for FY25, up 23% on prior year
• Glaucoma segment achieved positive EBITDA in H2 FY25, a substantial improvement
• Group cash outflow from operations reduced, with A$847,000 in Q4FY25

Nova Eye Medical Limited (ASX: EYE), a medical technology company committed to advanced ophthalmic treatment technologies and devices, has reported a record sales performance for the 2025 financial year. Total group revenue for FY25 reached A$29.2 million (US$18.8 million), marking a 23% increase on the prior year. Second-half sales of A$16.2 million (US$10.4 million) were up 51% on the prior corresponding period and in line with guidance. Fourth-quarter sales of A$8.8 million (US$5.7 million) represented the highest quarterly result in the company's history. The glaucoma segment achieved an EBITDA of US$65,000 (unaudited) in H2FY25, a substantial improvement on H1. At a group level, the second-half EBITDA loss was US$2.1 million lower than H1FY25. Quarterly group cash outflow from operations was A$847,000, representing a continuation of the downward trend in cash outflow. Cash on hand as of 30 June 2025 was A$5.1 million.

FY26 sales revenue (excluding China) expected to range between US$21 million and US$24 million (A$32 million to A$37 million). The group is currently expected to achieve breakeven EBITDA in H1 FY26.

The company expects the improvement in group profitability and cash flow from operations to continue in FY26.